What is tolvaptan’s “IP date” in Europe?
“IP date” usually refers to patent expiry and related market exclusivity dates that affect when generic or biosimilar competition can enter a European market. For tolvaptan, the exact date depends on the specific product (brand/company and strength), the jurisdiction (EU vs. individual countries), and whether you mean patent expiry or regulatory exclusivity (for example, supplementary protection certificates, SPCs).
To give a precise Europe date, I need one detail: which tolvaptan product are you referring to (brand name and/or marketing authorization holder)?
How do patent expiry and SPCs work for medicines like tolvaptan in Europe?
In Europe, the first patent that protects a drug substance may expire on one date, but an SPC can extend protection by adding years for the time taken to obtain marketing authorization. Courts and regulators can also narrow or invalidate particular claims, changing the practical “IP date” for market entry.
That means two companies can point to different dates depending on whether they are counting:
- the underlying patent expiry, or
- the SPC expiry, or
- the likely end date for enforceable, infringed claims for a specific generic filing.
Does Europe treat “EU-wide” dates the same way for market entry?
Not always. Even if an SPC or patent is granted/validated, enforcement actions and market-entry timing can still differ by country. Some “IP date” answers you’ll see are EU-wide (based on an SPC), while others are country-specific (based on local patent litigation outcomes and readiness of generics).
What does a competitor/generic company typically count as the relevant date?
Competitors usually base “entry timing” on when they can launch without infringing:
- the patent(s) they expect will be relevant to their specific product, and
- any SPC covering the same active ingredient and jurisdiction.
In practice, companies often cite a “latest expiry” date across the most likely-to-block rights, not just the earliest patent in the chain.
What I can do next if you share the brand/product
If you tell me the brand name (or marketing authorization holder) and whether you mean “patent expiry” or “SPC/exclusivity expiry,” I can help you narrow down the relevant Europe IP date and explain what it is based on.
Reply with either:
1) Brand name + country (e.g., “Samsca in EU/UK/DE/FR”), or
2) Marketing authorization holder/company name, or
3) The patent/SPC reference you’ve seen in a report.
Sources
No sources were provided with your question, so I can’t reliably cite tolvaptan’s Europe IP date. If you share a document/link (or the brand/product), I can extract the exact Europe date from it and cite it accurately.